Published in Arthritis Care Res (Hoboken) on February 01, 2015
Dosing Flexibility Study in Patients With Rheumatoid Arthritis (DoseFlex) | NCT00580840
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
A systematic review of the associations between dose regimens and medication compliance. Clin Ther (2001) 9.23
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum (2006) 4.61
Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol (2002) 4.37
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis (2008) 2.35
A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum (2007) 2.26
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther (2009) 1.98
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) (2008) 1.39
Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford) (2006) 1.35
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) (2009) 1.32
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) (2012) 1.31
Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J (2002) 1.24
Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther (2012) 0.98
Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford) (2012) 0.89
Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol (2007) 0.86
Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin (2009) 0.86
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 16.81
Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science (1966) 13.12
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature (2001) 6.76
Reactions in vivo and in vitro produced by a soluble substance associated with delayed-type hypersensitivity. Proc Natl Acad Sci U S A (1968) 4.57
The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A (2000) 4.01
c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest (2001) 3.86
Large-scale monitoring of pleiotropic regulation of gene expression by the prokaryotic nucleoid-associated protein, H-NS. Mol Microbiol (2001) 3.60
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
The children's depression inventory: a systematic evaluation of psychometric properties. J Consult Clin Psychol (1984) 3.41
Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev (1999) 3.41
Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol (1993) 3.14
Crude-oil biodegradation via methanogenesis in subsurface petroleum reservoirs. Nature (2007) 3.06
Multiple control of flagellum biosynthesis in Escherichia coli: role of H-NS protein and the cyclic AMP-catabolite activator protein complex in transcription of the flhDC master operon. J Bacteriol (1999) 2.80
Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr (1994) 2.63
D-penicillamine induced Goodpasture's syndrome in Wilson's disease. Ann Intern Med (1975) 2.56
Studies on the migration inhibitory factor associated with delayed-type hypersensitivity: cytodynamics and specificity. Transplantation (1967) 2.52
The filamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp. Mol Microbiol (1993) 2.39
Improving public health information: a data quality intervention in KwaZulu-Natal, South Africa. Bull World Health Organ (2011) 2.37
Hair concentrations of nicotine and cotinine in women and their newborn infants. JAMA (1994) 2.18
Migration inhibitory factor associated with delayed-type hypersensitivity. Fed Proc (1990) 2.02
Stroke physician versus stroke neurologist: can anyone thrombolyse? Intern Med J (2015) 2.02
Towards a better understanding of the genetic and physiological basis for nitrogen use efficiency in maize. Plant Physiol (2001) 2.01
Tenfold errors in administration of drug doses: a neglected iatrogenic disease in pediatrics. Pediatrics (1986) 2.01
Specific suppression of tumor growth by isolated peritoneal macrophages from immunized mice. J Immunol (1965) 1.90
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
Reconstitution of the [4Fe-4S] cluster in FNR and demonstration of the aerobic-anaerobic transcription switch in vitro. Biochem J (1996) 1.78
Epidemiological study of respiratory disease in workers exposed to polyvinylchloride dust. Thorax (1980) 1.69
Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry (1995) 1.67
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Determination of gestational cocaine exposure by hair analysis. JAMA (1989) 1.63
Prostatic calculi: a review. Prostate (1985) 1.62
Isolation and cultivation in vitro of macrophages from various sources in the mouse. Am J Pathol (1966) 1.59
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum (1999) 1.58
Aminoglycoside 6'-N-acetyltransferase variants of the Ib type with altered substrate profile in clinical isolates of Enterobacter cloacae and Citrobacter freundii. Antimicrob Agents Chemother (1998) 1.56
The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol (2000) 1.54
Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther (1999) 1.52
Emergence of optic pathway gliomas in children with neurofibromatosis type 1 after normal neuroimaging results. J Pediatr (1992) 1.51
Fat necrosis and inflammatory pseudotumor due to endoscopic tattooing of the colon with india ink. Gastrointest Endosc (1991) 1.50
A randomized trial of glyceryl trinitrate ointment and nitroglycerin patch in healing of anal fissures. Int J Colorectal Dis (2000) 1.47
antiphospholipid antibodies and RA: presence of beta2GP1 independent aCL. Ann Rheum Dis (2001) 1.44
Familial thrombosis: inherited deficiency of antithrombin III. Br Med J (1978) 1.40
Mutational analysis of the Bordetella pertussis fim/fha gene cluster: identification of a gene with sequence similarities to haemolysin accessory genes involved in export of FHA. Mol Microbiol (1994) 1.38
Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol (1988) 1.38
Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes. J Exp Med (1997) 1.37
Role of Escherichia coli histone-like nucleoid-structuring protein in bacterial metabolism and stress response--identification of targets by two-dimensional electrophoresis. Eur J Biochem (1997) 1.33
Sulfite:Cytochrome c oxidoreductase from Thiobacillus novellus. Purification, characterization, and molecular biology of a heterodimeric member of the sulfite oxidase family. J Biol Chem (2000) 1.31
NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol (2001) 1.28
Relation of the migration inhibitory factor (MIF) to delayed-type hypersensitivity reactions. Ann N Y Acad Sci (1970) 1.26
Xenopus Cyr61 regulates gastrulation movements and modulates Wnt signalling. Development (2003) 1.26
Template to improve glycemic control without reducing adiposity or dietary fat. Am J Physiol Endocrinol Metab (2011) 1.25
Divalent metal binding properties of the methionyl aminopeptidase from Escherichia coli. Biochemistry (2000) 1.23
Changes in antihemophilic factor (AHF, factor 8) procoagulant activity and AHF-like antigen in normal pregnancy, and following exercise and pneumoencephalography. J Lab Clin Med (1972) 1.21
Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr (1995) 1.20
Demonstration of delayed hypersensitivity to soluble antigens of chemically induced tumors by inhibition of macrophage migration. Proc Natl Acad Sci U S A (1969) 1.17
Self-administration of cocaine analogs by rats. Psychopharmacology (Berl) (1999) 1.17
Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Blood Coagul Fibrinolysis (1995) 1.16
Characterization of polyamine synthesis pathway in Bacillus subtilis 168. Mol Microbiol (1998) 1.16
Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol (1996) 1.16
Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. Cancer (1983) 1.16
Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol (1997) 1.15
Prevalence of fetal exposure to cocaine in Toronto, 1990-1991. Clin Invest Med (1994) 1.14
Clinical and psychological outcome from a randomized controlled trial of patient-initiated direct-access hospital follow-up for rheumatoid arthritis extended to 4 years. Rheumatology (Oxford) (2003) 1.13
Streptokinase in iliofemoral venous thrombosis. Br J Surg (1969) 1.13
Xanthogranulomatous pyelonephritis: detailed analysis of 29 cases and a brief discussion of atypical presentations. J Urol (1981) 1.13
Diagnosis of deep vein thrombosis using autologous indium-III-labelled platelets. Br Med J (Clin Res Ed) (1981) 1.12
Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J Clin Pathol (1984) 1.12
The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J Immunol (1984) 1.08
Development of a trehalose 6,6'-dimycolate model which explains cord formation by Mycobacterium tuberculosis. Infect Immun (1993) 1.08
Characterization of BpH3, an H-NS-like protein in Bordetella pertussis. Mol Microbiol (1997) 1.08
Microphthalmos with cyst: clinical presentations and computed tomographic findings. J Pediatr Ophthalmol Strabismus (1985) 1.07
Confirmation of quantitative trait loci for ethanol sensitivity in long-sleep and short-sleep mice. Genome Res (1997) 1.05
A locus involved in kanamycin, chloramphenicol and L-serine resistance is located in the bglY-galU region of the Escherichia coli K12 chromosome. Mol Gen Genet (1989) 1.05
Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health (Larchmt) (2003) 1.05
In vivo determination of the molecular composition of artery wall by intravascular Raman spectroscopy. Anal Chem (2000) 1.05
Panic disorder: cognitive-behavioral treatment. Behav Res Ther (1990) 1.05
Cunning-folk in the medical market-place during the nineteenth century. Med Hist (1999) 1.05
Exposure to vinyl chloride and angiosarcoma of the liver: a report of the register of cases. Br J Ind Med (1985) 1.04
Proteins of the fibrinolytic system in human thrombi. Thromb Haemost (1996) 1.04
Failure of standard magnetic resonance imaging in patients with refractory temporal lobe epilepsy. Arch Neurol (1998) 1.03
Passive smoking in children. Racial differences in systemic exposure to cotinine by hair and urine analysis. Chest (1996) 1.03
Intrahepatic and intramyocellular lipids are determinants of insulin resistance in prepubertal children. Diabetologia (2010) 1.03
Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int Immunol (1995) 1.02
Colchicine kinetics in patients with familial Mediterranean fever. Clin Pharmacol Ther (1980) 1.02
Indium-111 labelled platelets in diagnosis of leg-vein thrombosis: preliminary findings. Br Med J (1980) 1.02
Smoking among Saudi university students: consumption patterns and risk factors. East Mediterr Health J (2011) 1.02
The temporal stability and co-morbidity of prolonged fatigue: a longitudinal study in primary care. Psychol Med (1999) 1.02
Occupationally related angiosarcoma of the liver in the United Kingdom 1972-1994. Gut (1996) 1.02
Outcome in colorectal adenocarcinoma: two seven-year studies of a population. BMJ (1993) 1.02
Hemophilia A and von Willebrand's disease: the relationship examined. Ann N Y Acad Sci (1975) 1.01
Relationship between inbreeding depression and inbreeding coefficient in maritime pine (Pinus pinaster). Theor Appl Genet (1996) 1.01
Isolation and characterization of vicH, encoding a new pleiotropic regulator in Vibrio cholerae. J Bacteriol (2000) 1.01
Pneumoperitoneum as a risk factor for endobronchial intubation during laparoscopic gynecologic surgery. Anesth Analg (1998) 1.01
Experience with minimal complications in implanted catheters in children. Am J Pediatr Hematol Oncol (1989) 1.00
Evidence favoring molybdenum-carbon bond formation in xanthine oxidase action: 17Q- and 13C-ENDOR and kinetic studies. Biochemistry (1996) 1.00
Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol (1991) 0.99
Macrophages and delayed-type hypersensitivity. Semin Hematol (1970) 0.98
Condylomata acuminata of the urinary bladder. Natural history, viral typing, and DNA content. Am J Surg Pathol (1988) 0.98
Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol (1995) 0.98
The inhibition of urokinase by alpha 2 -macroglobulin. Clin Sci (1973) 0.97